Citadel Advisors’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-95,621
| Closed | -$4.57M | – | 14093 |
|
|
2025
Q3 | $4.57M | Buy |
+95,621
| New | +$2.65M | ﹤0.01% | 4527 |
|
|
2025
Q2 | – | Sell |
-570,588
| Closed | -$8.68M | – | 15130 |
|
|
2025
Q1 | $8.68M | Sell |
570,588
-77,530
| -12% | -$1.24M | ﹤0.01% | 3043 |
|
|
2024
Q4 | $13.1M | Buy |
648,118
+209,126
| +48% | +$5.27M | ﹤0.01% | 2632 |
|
|
2024
Q3 | $11.3M | Sell |
438,992
-47,976
| -10% | -$801K | ﹤0.01% | 2719 |
|
|
2024
Q2 | $6.26M | Buy |
486,968
+332,108
| +214% | +$5.34M | ﹤0.01% | 3406 |
|
|
2024
Q1 | $3.55M | Buy |
+154,860
| New | +$5.46M | ﹤0.01% | 4519 |
|
|
2023
Q4 | – | Sell |
-11,448
| Closed | -$322K | – | 15271 |
|
|
2023
Q3 | $322K | Sell |
11,448
-9,927
| -46% | -$291K | ﹤0.01% | 9035 |
|
|
2023
Q2 | $650K | Sell |
21,375
-83,138
| -80% | -$2.12M | ﹤0.01% | 7363 |
|
|
2023
Q1 | $1.96M | Sell |
104,513
-247,701
| -70% | -$4.09M | ﹤0.01% | 5411 |
|
|
2022
Q4 | $3.59M | Buy |
352,214
+85,957
| +32% | +$1.38M | ﹤0.01% | 4447 |
|
|
2022
Q3 | $7M | Sell |
266,257
-990
| -0.4% | -$36.1K | ﹤0.01% | 3317 |
|
|
2022
Q2 | $12.1M | Buy |
267,247
+888
| +0.3% | +$70.1K | ﹤0.01% | 2442 |
|
|
2022
Q1 | $26.2M | Buy |
266,359
+195
| +0.1% | +$18.2K | 0.01% | 1695 |
|
|
2021
Q4 | $40.7M | Sell |
266,164
-783
| -0.3% | -$116K | 0.01% | 1331 |
|
|
2021
Q3 | $35.4M | Sell |
266,947
-86
| -0% | -$11.8K | 0.01% | 1418 |
|
|
2021
Q2 | $38.1M | Buy |
+267,033
| New | +$40.9M | 0.01% | 1360 |
|
Citadel Advisors's TRML Position: Q4 2025 in Review
Citadel Advisors sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 95,621 shares — an estimated $4.57M sold.
Citadel Advisors first reported a position in TRML in Q2 2021 and held it in 16 quarters. The position peaked at $40.7M in Q4 2021. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- Citadel Advisors reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- Citadel Advisors sold 95,621 Tourmaline Bio shares in Q4 2025, an estimated $4.57M.
- Citadel Advisors first reported a position in Tourmaline Bio in Q2 2021 and held it in 16 quarters.
- Citadel Advisors's Tourmaline Bio position peaked at $40.7M in Q4 2021.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.